Synaptogenix (TAOX) Competitors $7.65 +1.20 (+18.60%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock TAOX vs. ATHE, KLRS, NBRV, GRCE, TELO, ENLV, SLGL, ATNF, ACRV, and GBIOShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Alterity Therapeutics (ATHE), Kalaris Therapeutics (KLRS), Nabriva Therapeutics (NBRV), Grace Therapeutics (GRCE), Telomir Pharmaceuticals (TELO), Enlivex Therapeutics (ENLV), Sol-Gel Technologies (SLGL), 180 Life Sciences (ATNF), Acrivon Therapeutics (ACRV), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Alterity Therapeutics Kalaris Therapeutics Nabriva Therapeutics Grace Therapeutics Telomir Pharmaceuticals Enlivex Therapeutics Sol-Gel Technologies 180 Life Sciences Acrivon Therapeutics Generation Bio Synaptogenix (NASDAQ:TAOX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability. Do insiders & institutionals have more ownership in TAOX or ATHE? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor TAOX or ATHE? In the previous week, Synaptogenix had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Alterity Therapeutics. Synaptogenix's average media sentiment score of 0.69 beat Alterity Therapeutics' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media. Company Overall Sentiment Synaptogenix Positive Alterity Therapeutics Neutral Do analysts rate TAOX or ATHE? Alterity Therapeutics has a consensus price target of $12.00, indicating a potential upside of 139.04%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, TAOX or ATHE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$20.16-0.38Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Which has more risk & volatility, TAOX or ATHE? Synaptogenix has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Is TAOX or ATHE more profitable? Alterity Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -277.76% -150.79% Alterity Therapeutics N/A N/A N/A SummaryAlterity Therapeutics beats Synaptogenix on 7 of the 11 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for TAOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAOX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$22.49M$832.60M$2.59B$9.58BDividend YieldN/A4.84%2.55%4.10%P/E Ratio-0.381.1722.0126.05Price / SalesN/A26.3482.73103.03Price / CashN/A19.5623.4758.48Price / Book1.556.6531.916.61Net Income-$12.77M-$4.94M$31.01M$265.56M7 Day Performance-8.93%1.08%1.04%1.97%1 Month PerformanceN/A2.03%1.14%-0.36%1 Year PerformanceN/A10.56%29.20%19.03% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAOXSynaptogenixN/A$7.65+18.6%N/AN/A$22.49MN/A-0.384Earnings ReportGap UpATHEAlterity Therapeutics2.2389 of 5 stars$5.21-0.4%$12.00+130.3%+280.3%$46.55MN/A0.0010KLRSKalaris Therapeutics1.3206 of 5 stars$2.46+8.4%$3.00+22.0%N/A$46.01MN/A0.00110Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070GRCEGrace Therapeutics3.0341 of 5 stars$3.26+5.8%$12.00+268.1%N/A$45.08MN/A-3.79N/APositive NewsTELOTelomir Pharmaceuticals2.7088 of 5 stars$1.49-5.1%$15.00+906.7%-74.4%$44.35MN/A-2.761Gap DownENLVEnlivex Therapeutics3.345 of 5 stars$1.82+2.2%$10.00+449.5%-18.6%$43.05MN/A-2.7670Upcoming EarningsShort Interest ↓High Trading VolumeSLGLSol-Gel Technologies1.0416 of 5 stars$15.44+1.2%$40.00+159.1%+226.2%$43.01M$11.54M-12.5550News CoverageEarnings ReportGap DownATNF180 Life Sciences0.5404 of 5 stars$7.04-7.5%N/A+135.8%$42.52MN/A-0.477ACRVAcrivon Therapeutics2.7919 of 5 stars$1.35-2.9%$17.57+1,201.6%-84.3%$42.47MN/A-0.6058GBIOGeneration Bio3.2056 of 5 stars$6.29-5.6%$37.33+493.5%-74.4%$42.37M$21.23M-0.58150 Related Companies and Tools Related Companies Alterity Therapeutics Alternatives Kalaris Therapeutics Alternatives Nabriva Therapeutics Alternatives Grace Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Enlivex Therapeutics Alternatives Sol-Gel Technologies Alternatives 180 Life Sciences Alternatives Acrivon Therapeutics Alternatives Generation Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TAOX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access